Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India
Sanofi Ends Dronedarone Sales Due To Low Commercial Interest
Executive Summary
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.